iPSC-derived RPE(National Eye Institute)

Background:
Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots. Researchers want to learn if replacing older eye cells with younger ones can help treat this disease.
Objective:
To test the safety of putting cells inside the eye as a possible future treatment for dry age-related macular degeneration.
Eligibility:
People ages 55 and older who have geographic atrophy with loss of vision. People who have had "wet" macular degeneration in study eye are NOT eligible.
Design:
Participants will be screened with:
* Medical history
* Physical exam
* Blood and urine tests
* Eye exam
* Eye photos
* Fluorescein angiography. An intravenous (IV) line is placed in an arm vein. A dye is injected. A camera takes pictures of the dye as it flows through the eyes' blood vessels.
* Electroretinography. An electrode is taped to participants' forehead. They sit in the dark. After 30 minutes, numbing eye drops and contact lenses are placed in their eyes. They watch flashing lights.
* Tuberculosis test
* Chest X-ray
* Electrocardiography. Sticky pads are placed on participants' chest to record the heart's electrical activity.
Participants will have at least 14 study visits over 5 and a half years. They will repeat screening tests.
Participants will have retinal pigment epithelium (RPE) transplantation surgery in one eye. For this, cells from participants' blood are turned into RPE cells. These cells are placed in their eye through a cut in their retina. They will get dilating eye drops, an IV line, and anesthesia that may make them sleep. A gas bubble will be put in their eye to help it heal. Participants will receive immunosuppressive medications to avoid transplant rejection.
Participants will be contacted yearly for up to 15 years.